Implications of Lung Shunt Fraction Calculation Discrepancy in Yttrium-90 Radioembolization Treatment from 2D Planar Vs 3D Single Photon Emission CT Imaging

Overview

Journal BJR Case Rep

Publisher Oxford University Press

Specialty Radiology

Date 2024 Jun 10

PMID 38854889

Authors

Paula Gamero Kubota

Christopher Molvar

Robert Wagner

Emad Allam

James Halama

Judy R James

Affiliations

Soon will be listed here.

Abstract

The safety and efficacy of Yttrium-90 (Y-90) radio-embolization therapy is partly dependent on the lung shunt fraction (LSF). There may be a notable disparity between LSF when calculated using 2D planar imaging vs 3D single photon emission CT (SPECT); this can affect the total allowable Y-90 dose delivered and therefore change the effectiveness of the procedure. The case presented demonstrates an 81% decrease in LSF when calculated by SPECT as compared to 2D planar imaging. This case highlights the importance of considering the imaging technique and the potential discrepancies that can arise between planar and SPECT imaging in LSF assessment.

References

Spina J, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R . Expected and Unexpected Imaging Findings after Y Transarterial Radioembolization for Liver Tumors. Radiographics. 2019; 39(2):578-595. DOI: 10.1148/rg.2019180095. View

Allred J, Niedbala J, Mikell J, Owen D, Frey K, Dewaraja Y . The value of Tc-MAA SPECT/CT for lung shunt estimation in Y radioembolization: a phantom and patient study. EJNMMI Res. 2018; 8(1):50. PMC: 6003896. DOI: 10.1186/s13550-018-0402-8. View

Salem R, Padia S, Lam M, Chiesa C, Haste P, Sangro B . Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2022; 50(2):328-343. PMC: 9816298. DOI: 10.1007/s00259-022-05956-w. View

Lam M, Garin E, Maccauro M, Kappadath S, Sze D, Turkmen C . A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022; 49(10):3340-3352. PMC: 9308596. DOI: 10.1007/s00259-022-05774-0. View

Braat A, Smits M, Braat M, van den Hoven A, Prince J, W A M de Jong H . ⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments. J Nucl Med. 2015; 56(7):1079-87. DOI: 10.2967/jnumed.115.157446. View

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T . Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020; 6(1):17-29. DOI: 10.1016/S2468-1253(20)30290-9. View

Mikell J, Dewaraja Y, Owen D . Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol. 2019; 30(1):68-76. PMC: 8063594. DOI: 10.1016/j.semradonc.2019.08.005. View

Struycken L, Patel M, Kuo P, Hennemeyer C, Woodhead G, McGregor H . Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic Y Radioembolization Using SPECT/CT Versus Planar Scintigraphy. AJR Am J Roentgenol. 2021; 218(4):728-737. DOI: 10.2214/AJR.21.26663. View

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

10.

Elsayed M, Cheng B, Xing M, Sethi I, Brandon D, Schuster D . Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?. Cardiovasc Intervent Radiol. 2020; 44(2):254-260. DOI: 10.1007/s00270-020-02638-8. View